Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imeglimin mechanism in Japanese type 2 diabetes using glucose clamp
jRCTs051220028Completed
- Sponsor
- Sumitomo Pharma
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of imeglimin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sumitomo Pharma. Primary endpoint: Incremental AUC of insulin concentration in hyperglycemic clamp between 0 and 10 minutes after 16 weeks. Started Jul 2022; status: completed.
02
Drugs
imeglimin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs051220028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051220028.